Next Article in Journal
Identification of Prognostic Markers of Gynecologic Cancers Utilizing Patient-Derived Xenograft Mouse Models
Previous Article in Journal
Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 14
Issue 3
10.3390/cancers14030827
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma

Cancers 2022, 14(3), 827; https://doi.org/10.3390/cancers14030827
by Ryu Sasaki 1,*, Kazuyoshi Nagata 1, Masanori Fukushima 1, Masafumi Haraguchi 1, Satoshi Miuma 1, Hisamitsu Miyaaki 1, Akihiko Soyama 2, Masaaki Hidaka 2, Susumu Eguchi 2, Masaya Shigeno 3, Mio Yamashima 4, Shinobu Yamamichi 4, Tatsuki Ichikawa 4, Yuki Kugiyama 5, Hiroshi Yatsuhashi 5 and Kazuhiko Nakao 1
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Cancers 2022, 14(3), 827; https://doi.org/10.3390/cancers14030827
Submission received: 16 January 2022 / Revised: 2 February 2022 / Accepted: 4 February 2022 / Published: 6 February 2022

Round 1

Reviewer 1 Report

The authors present a study wherein they conclude that hepatobiliary phase of EOB-MRI was useful in predicting the therapeutic efficacy/ outcome of atezolizumab plus bevacizumab therapy on unresectable HCC.

Authors need to describe heterogenous/homogenous subtypes and hyperintense/hypointense subtypes more clearly in the context of HCC and MRI. There is not sufficient information in the introduction.

Authors have recognized and mentioned the limitations of the present study such as small cohort size of patients, limitation of the assays to determine the extent of beta catenin mutations and others.

If possible, the authors must try to address these limitations, at least for the size of the patient cohort, for a conclusive study.

In addition, the authors should also improve on the grammatical errors and typos found in the manuscript.

 

In addition to

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

Sasaki et al. proposed an interesting work concerning MRI results in HCC management with immunotherapy.

They underlined the role of EOB-MRI in heterogenous lesiosn and its probable impact on management.

Nevertheless, thz study is retrospective, single-center.

I just note some revisions:

Major revision: an external review of the result is necessary, in the aim to shunt a bias. If not, it must be mentioned in discussion.

Minor revisions:

Eventual perspectives were not mentioned.

Analysis taking in account the other risk may probably more interesting.

Chracteristics of population arelacking some data, concerning tolerance for exemple.

 

 

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Round 2

Reviewer 2 Report

I read with attention revised manuscript and their responses: these responses and the midifications in the text seem to be accurate with my previous comments.

Back to TopTop